Nixon Peabody Trust Co. Has $4.58 Million Stake in Johnson & Johnson $JNJ

Nixon Peabody Trust Co. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,987 shares of the company’s stock after selling 10,168 shares during the period. Nixon Peabody Trust Co.’s holdings in Johnson & Johnson were worth $4,581,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GFG Capital LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth $48,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter valued at $52,000. Finally, Pandora Wealth Inc. bought a new position in Johnson & Johnson during the 1st quarter valued at $65,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on JNJ shares. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Raymond James Financial boosted their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $200.52.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $195.19 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $196.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s fifty day moving average price is $185.46 and its two-hundred day moving average price is $169.66. The firm has a market cap of $470.27 billion, a PE ratio of 18.84, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.